MedTrace Logo

Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects

NCT01915771 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-11

Study results available
· View outcomes & findings →

Summary

Objectives:

To evaluate the intra-subject variability of the pharmacokinetics (PK) of single oral capsule doses of 20 mg lomitapide.

Conditions

  • Intra-subject Variability of Pharmacokinetics

Interventions

DRUG

lomitapide

20 mg dose

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Sumeray, MD · Aegerion Pharmaceuticals, Inc.

  • Ulrike Lorch, MD · Richmond Pharmacology Limited

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-29
Primary Completion
2013-08-23
Completion
2013-08-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915771 on ClinicalTrials.gov